says Dawen Zhao, MD, PhD, associate professor of biomedical engineering at Wake Forest School of Medicine.
Novel Therapy against MPE
In addition, the abundance of tumor-associated immune cells in MPE prevents the recognition and elimination of cancer by the body’s immune system.
To overcome this normal physiological failure, the team developed a nanoparticle liposomal cyclic dinucleotide (LNP-CDN) for targeted activation of an immune pathway called STING. This helps reprogram tumor-associated immune cells to active anti-tumor ones.
It was observed that the combination of LNP-CDN with anti-PD-L1 immunotherapy (novel immunotherapy) resulted in prolonged survival by drastically reducing the volume of MPE and inhibiting the tumor growth in both the pleural cavity and lung tissue of mice with MPE.
“Administered alone or with immunotherapy, this study demonstrates a possible treatment for MPE. Given the current prognosis of MPE patients, new interventions are needed to not only prolong survival, but also to improve quality of life,” says, Zhao.
Source: Medindia
